Board Effectiveness
Impossibile aggiungere al carrello
Puoi avere soltanto 50 titoli nel carrello per il checkout.
Riprova più tardi
Riprova più tardi
Rimozione dalla Lista desideri non riuscita.
Riprova più tardi
Non è stato possibile aggiungere il titolo alla Libreria
Per favore riprova
Non è stato possibile seguire il Podcast
Per favore riprova
Esecuzione del comando Non seguire più non riuscita
-
Letto da:
-
Di:
A proposito di questo titolo
In this episode, Bridget and Cameron unpack the role AICD Not-for-profit Governance Principle 4: Board Effectiveness played in the case of Theranos, the Silicon Valley start-up that wasn't quite what it seemed. The company touted a breakthrough in health technology through the use of small automated devices and in 2014 was valued at around $10 billion. However, the technology was not what founder Elizabeth Holmes claimed and she was charged with fraud in 2018.
Highly experienced board member and Chair of Spirit Super, Naomi Edwards, helps the team assess how a stronger focus on board effectiveness may have exposed the problems overlooked by the Theranos board and helped to mitigate the damage.
Episode Guide:
- 0:32 — Overview of Principle 4: Board Effectiveness
- 5:44 — Interview with Naomi Edwards about what an effective board looks like and how this principle may have helped in the long-running Theranos saga
- 39:29 — Wrap-up
Ancora nessuna recensione